Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload. 1985

A I Schafer, and S Rabinowe, and M S Le Boff, and K Bridges, and R G Cheron, and R Dluhy

Transfusional iron overload in adult patients with acquired anemias may result in widespread organ dysfunction. Long-term deferoxamine mesylate therapy was administered by continuous subcutaneous infusion to six such patients, who have been followed up for up to 66 months of therapy while continuing to be transfusion-dependent. During deferoxamine therapy, liver density by computed tomographic scan decreased in four of five patients, liver iron content decreased in two of three patients, and liver function normalized in two patients. Plasma cortisol response to insulin-induced hypoglycemia improved in three of five patients receiving therapy. Pituitary growth hormone reserve normalized in two patients and remained normal in the other three tested. One patient, treated concurrently with ascorbic acid, died suddenly. The other five patients have had no cardiac deterioration by noninvasive testing. We conclude that long-term deferoxamine iron chelation therapy is effective not only in retarding but, in some cases, even reversing organ damage caused by transfusional iron overload.

UI MeSH Term Description Entries
D007501 Iron A metallic element with atomic symbol Fe, atomic number 26, and atomic weight 55.85. It is an essential constituent of HEMOGLOBINS; CYTOCHROMES; and IRON-BINDING PROTEINS. It plays a role in cellular redox reactions and in the transport of OXYGEN. Iron-56,Iron 56
D007502 Iron Chelating Agents Organic chemicals that form two or more coordination links with an iron ion. Once coordination has occurred, the complex formed is called a chelate. The iron-binding porphyrin group of hemoglobin is an example of a metal chelate found in biological systems. Iron Chelates,Agents, Iron Chelating,Chelates, Iron,Chelating Agents, Iron
D008111 Liver Function Tests Blood tests that are used to evaluate how well a patient's liver is working and also to help diagnose liver conditions. Function Test, Liver,Function Tests, Liver,Liver Function Test,Test, Liver Function,Tests, Liver Function
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012010 Red-Cell Aplasia, Pure Suppression of erythropoiesis with little or no abnormality of leukocyte or platelet production. Aplasia Pure Red Cell,Erythrocyte Aplasia,Pure Red-Cell Aplasia,Aplasia, Erythrocyte,Aplasia, Pure Red-Cell,Aplasias, Erythrocyte,Erythrocyte Aplasias,Pure Red Cell Aplasia,Pure Red-Cell Aplasias,Red Cell Aplasia, Pure,Red-Cell Aplasias, Pure
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003676 Deferoxamine Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form. Desferrioxamine,Deferoxamine B,Deferoxamine Mesilate,Deferoxamine Mesylate,Deferoxamine Methanesulfonate,Deferoximine,Deferrioxamine B,Desferal,Desferioximine,Desferrioxamine B,Desferrioxamine B Mesylate,Desferroxamine,Mesilate, Deferoxamine,Mesylate, Deferoxamine,Mesylate, Desferrioxamine B,Methanesulfonate, Deferoxamine
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral
D006486 Hemosiderosis Conditions in which there is a generalized increase in the iron stores of body tissues, particularly of liver and the MONONUCLEAR PHAGOCYTE SYSTEM, without demonstrable tissue damage. The name refers to the presence of stainable iron in the tissue in the form of hemosiderin. Hemosideroses

Related Publications

A I Schafer, and S Rabinowe, and M S Le Boff, and K Bridges, and R G Cheron, and R Dluhy
December 2000, Transfusion science,
A I Schafer, and S Rabinowe, and M S Le Boff, and K Bridges, and R G Cheron, and R Dluhy
July 2009, [Rinsho ketsueki] The Japanese journal of clinical hematology,
A I Schafer, and S Rabinowe, and M S Le Boff, and K Bridges, and R G Cheron, and R Dluhy
May 2012, European journal of haematology,
A I Schafer, and S Rabinowe, and M S Le Boff, and K Bridges, and R G Cheron, and R Dluhy
January 2011, Hemoglobin,
A I Schafer, and S Rabinowe, and M S Le Boff, and K Bridges, and R G Cheron, and R Dluhy
July 2003, Blood,
A I Schafer, and S Rabinowe, and M S Le Boff, and K Bridges, and R G Cheron, and R Dluhy
February 1981, The New England journal of medicine,
A I Schafer, and S Rabinowe, and M S Le Boff, and K Bridges, and R G Cheron, and R Dluhy
January 1993, Bone marrow transplantation,
A I Schafer, and S Rabinowe, and M S Le Boff, and K Bridges, and R G Cheron, and R Dluhy
January 2002, Advances in experimental medicine and biology,
A I Schafer, and S Rabinowe, and M S Le Boff, and K Bridges, and R G Cheron, and R Dluhy
December 2007, Leukemia research,
A I Schafer, and S Rabinowe, and M S Le Boff, and K Bridges, and R G Cheron, and R Dluhy
October 1997, European journal of haematology,
Copied contents to your clipboard!